Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03263559 · ClinicalTrials.gov registry record · Phase 2

Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)

A Phase 2 study of Sickle Cell Disease, sponsored by Medical College of Wisconsin.

Completed
Registry status
Phase 2
Development phase
95
Enrollment target
20
Study locations

NCT03263559 is a Phase 2 study of Sickle Cell Disease that has completed, run by Medical College of Wisconsin. The registered enrollment target is 95 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03263559, a Phase 2 study of Sickle Cell Disease, has completed, sponsored by Medical College of Wisconsin.

COMPLETED
Registry status
Phase 2
Development phase
95 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase II, single arm, multi-center trial, designed to estimate the efficacy and toxicity of haploidentical bone marrow transplantation (BMT) in patients with sickle cell disease (SCD). Based on their age and entry criteria patients are stratified into two groups: (1) children with severe SCD; and (2) adults with severe SCD.

Conditions Studied

Sickle Cell Disease

Interventions

  • DRUG Fludarabine
  • DRUG Hydroxyurea
  • DRUG Thiotepa
  • PROCEDURE Haploidentical Bone Marrow Transplantation
  • DRUG Rabbit-ATG

Study Locations (20)

Florida

  • University of Florida College of Medicine - Gainesville
  • Nicklaus Children's Hospital/University of Miami Children's Hospital - Miami
  • H. Lee Moffitt Cancer Center - Tampa

Indiana

  • Riley Children's Hospital at IU Health - Indianapolis
  • Indiana University Medical Center - Indianapolis

Michigan

  • Children's Hospital of Michigan - Detroit
  • Helen Devos Children's at Spectrum Health - Grand Rapids

Missouri

  • Cardinal Glennon Children's Hospital - St Louis
  • Washington University, St. Louis - St Louis

New York

  • Roswell Park Cancer Center - Buffalo
  • Northwell Health/Monter Cancer Center - Lake Success

North Carolina

  • Levine Children's Hospital - Charlotte
  • Duke University Medical Center - Durham

Alabama

  • University of Alabama at Birmingham - Birmingham

California

  • UCSF Benioff Children's Hospital Oakland - Oakland

Trial Details

FieldValue
Enrollment Target 95 participants
Start Date 2017-10-03
Est. Completion 2025-01-29
Phase Phase 2

Sponsor

Medical College of Wisconsin

447 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03263559

The ClinicalTrials.gov registry entry for NCT03263559 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (67% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.

NCT03263559 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Indiana, Michigan.

Frequently Asked Questions

What is clinical trial NCT03263559 about?

NCT03263559 is a clinical study titled "Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)". This is a Phase II, single arm, multi-center trial, designed to estimate the efficacy and toxicity of haploidentical bone marrow transplantation (BMT) in patients with sickle cell disease (SCD). Based on their age and entry criteria patients are stratified into two groups: (1) children with severe S...

What is the current status of trial NCT03263559?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2017-10-03. Estimated completion is 2025-01-29.

What conditions does trial NCT03263559 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

What interventions are being tested in trial NCT03263559?

The interventions under investigation include: Fludarabine (DRUG), Hydroxyurea (DRUG), Thiotepa (DRUG), Haploidentical Bone Marrow Transplantation (PROCEDURE), Rabbit-ATG (DRUG).

Who is sponsoring clinical trial NCT03263559?

This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03263559 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sickle Cell Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.